OxTalks is Changing
During Michaelmas Term, OxTalks will be moving to a new platform (full details are available on the Staff Gateway).
For now, continue using the current page and event submission process (freeze period dates to be advised).
If you have any questions, please contact halo@digital.ox.ac.uk
Genetics and Drug discovery
Novo Nordisk Research Centre Oxford (NNRCO) is an innovative target discovery unit with a focus on identifying novel, game-changing therapies for patients with type 2 diabetes and cardiometabolic diseases.
They employ advanced computational biology, state-of-the-art discovery screening technologies, genetics and human-centric cell systems to dissect pathophysiology and identify novel drug targets. The site is a fusion of the best of academia, biotech and big pharma in order to realize cutting-edge biology and start a target’s journey from bench to bedside.
NNRCO operates at the boundaries of frontier science with a mandate to find dynamic, agile and distinctive new ways of working to diversify the company’s pipeline with disruptive medicines.
Date:
7 September 2023, 12:00
Venue:
IMS-Tetsuya Nakamura Building, Roosevelt Dr, Headington OX3 7TY
Venue Details:
Large ground floor seminar room
Speaker:
Jo Howson (Novo Nordisk)
Organising department:
Medical Sciences Division
Organisers:
Eneida Parizotto (University of Oxford),
Sheena Lee (MSD Business Partnerships Office),
Medical Sciences Division Business Partnerships Office (University of Oxford)
Organiser contact email address:
sheena.lee@medsci.ox.ac.uk
Host:
Eneida Parizotto (University of Oxford)
Part of:
Industry Insight Seminar Series
Booking required?:
Required
Booking url:
https://www.eventbrite.co.uk/e/industry-insights-seminar-series-tickets-131313804123
Cost:
None
Audience:
Members of the University of Oxford and the UK Biotech/Pharma industry
Editor:
Sheena Lee
